Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study
RTX demonstrated comparable safety and efficacy as CY in patients with SSc-ILD. Thus, RTX may be an alternative to CY for the treatment of SSc-ILD.
Authors
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0002-2699-6876)
- Akie Hirata (ORCID: https://orcid.org/0000-0003-4211-3356)
- Shotaro Kawano (ORCID: https://orcid.org/0000-0002-5221-1008)
- Masahiro Ayano (ORCID: https://orcid.org/0000-0002-2954-9676)
- Junki Hiura
- R. Hiura
- Sho Fujimoto (ORCID: https://orcid.org/0000-0002-2671-1690)
- Fumiaki Sagawa
- Shunichiro Ota (ORCID: https://orcid.org/0000-0001-7395-1673)
- Ayako Takaki-Kuwahara
- Yasutaka Kimoto (ORCID: https://orcid.org/0000-0002-0158-2917)
- Hiroaki Niiro (ORCID: https://orcid.org/0000-0003-0914-9066)
- Naoya Nishimura
- Ayumi Uchino
- Koichi Akashi (ORCID: https://orcid.org/0000-0001-7763-5723)
- Seiji Yoshizawa
- Naoyasu Ueda
Institutions
- Kyushu University (JP)
- Kyushu University Hospital (JP)
- Hamanomachi Hospital (JP)
- Miyazaki Prefectural Hospital (JP)
- Shimonoseki City Hospital (JP)
- Japanese Red Cross Fukuoka Hospital (JP)
- Aso Iizuka Hospital (JP)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1186/s13075-025-03654-0
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science